25 XP   0   0   10

Astellas Pharma Inc
Buy, Hold or Sell?

Let's analyse Astellas together

PenkeI guess you are interested in Astellas Pharma Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Astellas Pharma Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Astellas Pharma Inc

I send you an email if I find something interesting about Astellas Pharma Inc.

Quick analysis of Astellas (30 sec.)










What can you expect buying and holding a share of Astellas? (30 sec.)

How much money do you get?

How much money do you get?
$0.42
When do you have the money?
1 year
How often do you get paid?
75.0%

What is your share worth?

Current worth
$5.43
Expected worth in 1 year
$5.26
How sure are you?
77.5%

+ What do you gain per year?

Total Gains per Share
$0.25
Return On Investment
2.7%

For what price can you sell your share?

Current Price per Share
$9.47
Expected price per share
$0 - $11.15
How sure are you?
50%

1. Valuation of Astellas (5 min.)




Live pricePrice per Share (EOD)

$9.47

Intrinsic Value Per Share

$-5.41 - $5.44

Total Value Per Share

$0.02 - $10.87

2. Growth of Astellas (5 min.)




Is Astellas growing?

Current yearPrevious yearGrowGrow %
How rich?$9.7b$10.1b$15.7m0.2%

How much money is Astellas making?

Current yearPrevious yearGrowGrow %
Making money$94.2k$221.7m-$221.6m-235,125.9%
Net Profit Margin-0.3%8.6%--

How much money comes from the company's main activities?

3. Financial Health of Astellas (5 min.)




What can you expect buying and holding a share of Astellas? (5 min.)

Welcome investor! Astellas's management wants to use your money to grow the business. In return you get a share of Astellas.

What can you expect buying and holding a share of Astellas?

First you should know what it really means to hold a share of Astellas. And how you can make/lose money.

Speculation

The Price per Share of Astellas is $9.47. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Astellas.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Astellas, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $5.43. Based on the TTM, the Book Value Change Per Share is $-0.04 per quarter. Based on the YOY, the Book Value Change Per Share is $0.11 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.11 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Astellas.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps0.050.6%0.000.0%0.121.3%0.111.1%0.121.2%
Usd Book Value Change Per Share-0.52-5.4%-0.04-0.4%0.111.2%0.050.6%0.050.5%
Usd Dividend Per Share0.232.4%0.111.1%0.151.6%0.121.3%0.090.9%
Usd Total Gains Per Share-0.29-3.0%0.060.7%0.262.8%0.171.8%0.141.4%
Usd Price Per Share11.90-13.71-14.91-15.14-14.67-
Price to Earnings Ratio56.77--147.06--13.02--13.09-197.50-
Price-to-Total Gains Ratio-41.22--7.68--6.61-37.12--23.61-
Price to Book Ratio2.19-2.44-2.71-3.05-3.31-
Price-to-Total Gains Ratio-41.22--7.68--6.61-37.12--23.61-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share9.47
Number of shares105
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.110.12
Usd Book Value Change Per Share-0.040.05
Usd Total Gains Per Share0.060.17
Gains per Quarter (105 shares)6.5918.19
Gains per Year (105 shares)26.3872.77
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
144-1816512263
288-364210144136
3133-546815267209
4177-719420289282
5221-89120253111355
6265-107146303133428
7310-125172354156501
8354-143198404178574
9398-161224455200647
10442-179250505222720

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share2.02.00.050.0%8.04.00.066.7%16.04.00.080.0%36.04.00.090.0%50.06.00.089.3%
Book Value Change Per Share2.02.00.050.0%8.04.00.066.7%14.06.00.070.0%28.012.00.070.0%37.017.02.066.1%
Dividend per Share2.00.02.050.0%10.00.02.083.3%16.00.04.080.0%30.00.010.075.0%37.00.019.066.1%
Total Gains per Share2.02.00.050.0%9.03.00.075.0%16.04.00.080.0%31.09.00.077.5%43.013.00.076.8%

Fundamentals of Astellas

About Astellas Pharma Inc

Astellas Pharma Inc. manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer. It also offers Evrenzo, a treatment for anemia associated with chronic kidney disease; Betanis/Myrabetriq/BETMIGA, a treatment for overactive bladder; and Prograf and Advagraf/Graceptor/ASTAGRAF XL immunosuppressants. Th company has a research collaboration with Vivtex Corporation to evaluate Vivtex's GI-ORIS screening and formulation platform technology to support the development of novel and oral versions of a therapeutic candidate provided by Astellas; and a partnership agreement with Roche Diabetes Care Japan Co., Ltd. to develop and commercialize integrated diabetes self-management solution. The company was founded in 1923 and is headquartered in Tokyo, Japan.

Fundamental data was last updated by Penke on 2024-04-19 04:46:06.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is not making a profit/loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating less efficient.
The company is less efficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is just able to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Astellas Pharma Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Astellas earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Astellas to the Drug Manufacturers - General industry mean.
  • A Net Profit Margin of 3.4% means that $0.03 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Astellas Pharma Inc:

  • The MRQ is 3.4%. The company is making a profit. +1
  • The TTM is -0.3%. The company is not making a profit/loss.
Trends
Current periodCompared to+/- 
MRQ3.4%TTM-0.3%+3.7%
TTM-0.3%YOY8.6%-8.9%
TTM-0.3%5Y9.1%-9.3%
5Y9.1%10Y11.4%-2.4%
1.1.2. Return on Assets

Shows how efficient Astellas is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Astellas to the Drug Manufacturers - General industry mean.
  • 0.4% Return on Assets means that Astellas generated $0.00 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Astellas Pharma Inc:

  • The MRQ is 0.4%. Using its assets, the company is inefficient in making profit. -1
  • The TTM is -0.1%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ0.4%TTM-0.1%+0.5%
TTM-0.1%YOY1.3%-1.4%
TTM-0.1%5Y1.4%-1.5%
5Y1.4%10Y1.9%-0.6%
1.1.3. Return on Equity

Shows how efficient Astellas is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Astellas to the Drug Manufacturers - General industry mean.
  • 1.0% Return on Equity means Astellas generated $0.01 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Astellas Pharma Inc:

  • The MRQ is 1.0%. Using its investors money, the company is inefficient in making profit. -1
  • The TTM is 0.0%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ1.0%TTM0.0%+1.0%
TTM0.0%YOY2.1%-2.1%
TTM0.0%5Y2.2%-2.2%
5Y2.2%10Y2.9%-0.7%

1.2. Operating Efficiency of Astellas Pharma Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Astellas is operating .

  • Measures how much profit Astellas makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Astellas to the Drug Manufacturers - General industry mean.
  • An Operating Margin of 9.4% means the company generated $0.09  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Astellas Pharma Inc:

  • The MRQ is 9.4%. The company is operating less efficient.
  • The TTM is 12.7%. The company is operating less efficient.
Trends
Current periodCompared to+/- 
MRQ9.4%TTM12.7%-3.3%
TTM12.7%YOY17.1%-4.4%
TTM12.7%5Y17.5%-4.7%
5Y17.5%10Y18.6%-1.1%
1.2.2. Operating Ratio

Measures how efficient Astellas is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Drug Manufacturers - General industry mean).
  • An Operation Ratio of 0.91 means that the operating costs are $0.91 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Astellas Pharma Inc:

  • The MRQ is 0.906. The company is less efficient in keeping operating costs low.
  • The TTM is 0.873. The company is less efficient in keeping operating costs low.
Trends
Current periodCompared to+/- 
MRQ0.906TTM0.873+0.033
TTM0.873YOY0.829+0.044
TTM0.8735Y0.835+0.038
5Y0.83510Y0.830+0.005

1.3. Liquidity of Astellas Pharma Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Astellas is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Drug Manufacturers - General industry mean).
  • A Current Ratio of 0.91 means the company has $0.91 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Astellas Pharma Inc:

  • The MRQ is 0.910. The company is just not able to pay all its short-term debts. -1
  • The TTM is 1.161. The company is just able to pay all its short-term debts.
Trends
Current periodCompared to+/- 
MRQ0.910TTM1.161-0.251
TTM1.161YOY1.397-0.236
TTM1.1615Y1.420-0.259
5Y1.42010Y1.841-0.421
1.3.2. Quick Ratio

Measures if Astellas is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Astellas to the Drug Manufacturers - General industry mean.
  • A Quick Ratio of 0.69 means the company can pay off $0.69 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Astellas Pharma Inc:

  • The MRQ is 0.686. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.921. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.686TTM0.921-0.235
TTM0.921YOY1.129-0.208
TTM0.9215Y1.125-0.204
5Y1.12510Y1.505-0.380

1.4. Solvency of Astellas Pharma Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Astellas assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Astellas to Drug Manufacturers - General industry mean.
  • A Debt to Asset Ratio of 0.55 means that Astellas assets are financed with 55.4% credit (debt) and the remaining percentage (100% - 55.4%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Astellas Pharma Inc:

  • The MRQ is 0.554. The company is able to pay all its debts by selling its assets. +1
  • The TTM is 0.478. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.554TTM0.478+0.075
TTM0.478YOY0.373+0.106
TTM0.4785Y0.399+0.079
5Y0.39910Y0.341+0.058
1.4.2. Debt to Equity Ratio

Measures if Astellas is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Astellas to the Drug Manufacturers - General industry mean.
  • A Debt to Equity ratio of 124.1% means that company has $1.24 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Astellas Pharma Inc:

  • The MRQ is 1.241. The company is able to pay all its debts with equity. +1
  • The TTM is 0.951. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ1.241TTM0.951+0.290
TTM0.951YOY0.594+0.357
TTM0.9515Y0.681+0.270
5Y0.68110Y0.538+0.143

2. Market Valuation of Astellas Pharma Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Astellas generates.

  • Above 15 is considered overpriced but always compare Astellas to the Drug Manufacturers - General industry mean.
  • A PE ratio of 56.77 means the investor is paying $56.77 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Astellas Pharma Inc:

  • The EOD is 45.180. Based on the earnings, the company is overpriced. -1
  • The MRQ is 56.773. Based on the earnings, the company is expensive. -2
  • The TTM is -147.059. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD45.180MRQ56.773-11.593
MRQ56.773TTM-147.059+203.832
TTM-147.059YOY-13.017-134.043
TTM-147.0595Y-13.086-133.974
5Y-13.08610Y197.503-210.589
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Astellas Pharma Inc:

  • The EOD is 17.343. Based on how much money comes from the company's main activities, the company is underpriced. +1
  • The MRQ is 21.793. Based on how much money comes from the company's main activities, the company is underpriced. +1
  • The TTM is -27.422. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD17.343MRQ21.793-4.450
MRQ21.793TTM-27.422+49.215
TTM-27.422YOY26.084-53.506
TTM-27.4225Y752.510-779.931
5Y752.51010Y390.961+361.549
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Astellas is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Drug Manufacturers - General industry mean).
  • A PB ratio of 2.19 means the investor is paying $2.19 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Astellas Pharma Inc:

  • The EOD is 1.745. Based on the equity, the company is underpriced. +1
  • The MRQ is 2.192. Based on the equity, the company is underpriced. +1
  • The TTM is 2.438. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD1.745MRQ2.192-0.448
MRQ2.192TTM2.438-0.245
TTM2.438YOY2.709-0.271
TTM2.4385Y3.050-0.613
5Y3.05010Y3.309-0.259
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Astellas Pharma Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.515-0.043-92%0.114-551%0.053-1073%0.047-1193%
Book Value Per Share--5.4285.623-3%5.529-2%5.028+8%4.515+20%
Current Ratio--0.9101.161-22%1.397-35%1.420-36%1.841-51%
Debt To Asset Ratio--0.5540.478+16%0.373+49%0.399+39%0.341+63%
Debt To Equity Ratio--1.2410.951+30%0.594+109%0.681+82%0.538+130%
Dividend Per Share--0.2270.105+115%0.150+51%0.120+88%0.090+152%
Eps--0.0520.000+18067%0.122-57%0.108-51%0.118-56%
Free Cash Flow Per Share--0.1370.119+14%0.164-17%0.168-19%0.175-22%
Free Cash Flow To Equity Per Share---0.1780.554-132%0.016-1177%0.182-197%0.115-255%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max--5.441--------
Intrinsic Value_10Y_min---5.407--------
Intrinsic Value_1Y_max--0.677--------
Intrinsic Value_1Y_min--0.432--------
Intrinsic Value_3Y_max--1.934--------
Intrinsic Value_3Y_min--0.462--------
Intrinsic Value_5Y_max--3.070--------
Intrinsic Value_5Y_min---0.425--------
Market Cap16979614845.440-26%21422558500.00024673972058.800-13%27256904751.885-21%27963477443.769-23%28951590385.099-26%
Net Profit Margin--0.034-0.003+108%0.086-60%0.091-62%0.114-70%
Operating Margin--0.0940.127-26%0.171-45%0.175-46%0.186-49%
Operating Ratio--0.9060.873+4%0.829+9%0.835+9%0.830+9%
Pb Ratio1.745-26%2.1922.438-10%2.709-19%3.050-28%3.309-34%
Pe Ratio45.180-26%56.773-147.059+359%-13.017+123%-13.086+123%197.503-71%
Price Per Share9.470-26%11.90013.705-13%14.908-20%15.139-21%14.674-19%
Price To Free Cash Flow Ratio17.343-26%21.793-27.422+226%26.084-16%752.510-97%390.961-94%
Price To Total Gains Ratio-32.806+20%-41.225-7.683-81%-6.611-84%37.117-211%-23.613-43%
Quick Ratio--0.6860.921-25%1.129-39%1.125-39%1.505-54%
Return On Assets--0.004-0.001+118%0.013-68%0.014-69%0.019-78%
Return On Equity--0.0100.000+102%0.021-54%0.022-56%0.029-66%
Total Gains Per Share---0.2890.063-560%0.264-209%0.173-267%0.137-311%
Usd Book Value--9771151000.00010122074625.000-3%10106370625.000-3%9268007125.000+5%8840099612.500+11%
Usd Book Value Change Per Share---0.515-0.043-92%0.114-551%0.053-1073%0.047-1193%
Usd Book Value Per Share--5.4285.623-3%5.529-2%5.028+8%4.515+20%
Usd Dividend Per Share--0.2270.105+115%0.150+51%0.120+88%0.090+152%
Usd Eps--0.0520.000+18067%0.122-57%0.108-51%0.118-56%
Usd Free Cash Flow--245752000.000215686250.000+14%299412750.000-18%311376325.000-21%344258687.500-29%
Usd Free Cash Flow Per Share--0.1370.119+14%0.164-17%0.168-19%0.175-22%
Usd Free Cash Flow To Equity Per Share---0.1780.554-132%0.016-1177%0.182-197%0.115-255%
Usd Market Cap16979614845.440-26%21422558500.00024673972058.800-13%27256904751.885-21%27963477443.769-23%28951590385.099-26%
Usd Price Per Share9.470-26%11.90013.705-13%14.908-20%15.139-21%14.674-19%
Usd Profit--94334500.00094250.000+99990%221700375.000-57%200106725.000-53%248556912.500-62%
Usd Revenue--2742558000.0002507899875.000+9%2385881875.000+15%2228051475.000+23%2168565912.500+26%
Usd Total Gains Per Share---0.2890.063-560%0.264-209%0.173-267%0.137-311%
 EOD+5 -3MRQTTM+14 -21YOY+6 -295Y+9 -2610Y+10 -25

3.2. Fundamental Score

Let's check the fundamental score of Astellas Pharma Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-1545.180
Price to Book Ratio (EOD)Between0-11.745
Net Profit Margin (MRQ)Greater than00.034
Operating Margin (MRQ)Greater than00.094
Quick Ratio (MRQ)Greater than10.686
Current Ratio (MRQ)Greater than10.910
Debt to Asset Ratio (MRQ)Less than10.554
Debt to Equity Ratio (MRQ)Less than11.241
Return on Equity (MRQ)Greater than0.150.010
Return on Assets (MRQ)Greater than0.050.004
Total3/10 (30.0%)

3.3. Technical Score

Let's check the technical score of Astellas Pharma Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5025.146
Ma 20Greater thanMa 5010.389
Ma 50Greater thanMa 10010.701
Ma 100Greater thanMa 20011.246
OpenGreater thanClose9.460
Total0/5 (0.0%)



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in JPY. All numbers in thousands.

Summary
Total Assets3,368,682,000
Total Liabilities1,865,428,000
Total Stockholder Equity1,503,255,000
 As reported
Total Liabilities 1,865,428,000
Total Stockholder Equity+ 1,503,255,000
Total Assets = 3,368,682,000

Assets

Total Assets3,368,682,000
Total Current Assets1,050,102,000
Long-term Assets2,318,580,000
Total Current Assets
Cash And Cash Equivalents 253,978,000
Short-term Investments 31,458,000
Net Receivables 505,905,000
Inventory 225,980,000
Other Current Assets 64,239,000
Total Current Assets  (as reported)1,050,102,000
Total Current Assets  (calculated)1,081,560,000
+/- 31,458,000
Long-term Assets
Property Plant Equipment 289,029,000
Goodwill 387,969,000
Intangible Assets 1,452,341,000
Long-term Assets Other 8,593,000
Long-term Assets  (as reported)2,318,580,000
Long-term Assets  (calculated)2,137,932,000
+/- 180,648,000

Liabilities & Shareholders' Equity

Total Current Liabilities1,153,715,000
Long-term Liabilities711,713,000
Total Stockholder Equity1,503,255,000
Total Current Liabilities
Short-term Debt 407,177,000
Short Long Term Debt 407,177,000
Accounts payable 150,426,000
Other Current Liabilities 561,290,000
Total Current Liabilities  (as reported)1,153,715,000
Total Current Liabilities  (calculated)1,526,070,000
+/- 372,355,000
Long-term Liabilities
Long term Debt 463,804,000
Long-term Liabilities Other 44,145,000
Long-term Liabilities  (as reported)711,713,000
Long-term Liabilities  (calculated)507,949,000
+/- 203,764,000
Total Stockholder Equity
Common Stock103,001,000
Retained Earnings 838,621,000
Accumulated Other Comprehensive Income 412,798,000
Other Stockholders Equity 148,835,000
Total Stockholder Equity (as reported)1,503,255,000
Total Stockholder Equity (calculated)1,503,255,000
+/-0
Other
Capital Stock103,001,000
Cash and Short Term Investments 253,978,000
Common Stock Shares Outstanding 1,800,215
Current Deferred Revenue34,822,000
Liabilities and Stockholders Equity 3,368,683,000
Net Debt 716,672,000
Net Invested Capital 2,374,236,000
Net Working Capital -103,613,000
Short Long Term Debt Total 970,650,000



Balance Sheet

Currency in JPY. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-312009-12-312009-09-302009-06-302009-03-312008-12-312008-09-30
> Total Assets 
0
0
1,348,446,000
0
1,386,961,000
1,362,910,000
1,364,176,000
1,341,307,000
1,355,246,000
1,302,318,000
1,335,091,000
1,351,736,000
1,326,941,000
1,358,841,000
1,400,629,000
1,336,129,000
1,319,494,000
1,418,079,000
1,445,561,000
1,471,067,000
1,497,122,000
1,565,175,000
1,653,108,000
1,616,276,000
1,715,340,000
1,851,850,000
1,793,578,000
1,780,003,000
1,770,678,000
1,787,802,000
1,799,338,000
1,693,626,000
1,713,181,000
1,853,939,000
1,820,901,000
1,901,237,000
1,895,713,000
1,933,831,000
1,858,205,000
1,866,551,000
1,886,926,000
1,928,325,000
1,897,648,000
1,927,031,000
1,979,816,000
1,989,779,000
2,318,160,000
2,256,035,000
2,237,016,000
2,296,843,000
2,273,628,000
2,249,456,000
2,261,508,000
2,356,245,000
2,332,395,000
2,481,843,000
2,583,661,000
2,513,948,000
2,456,518,000
2,797,958,000
3,543,021,000
3,368,682,000
3,368,682,0003,543,021,0002,797,958,0002,456,518,0002,513,948,0002,583,661,0002,481,843,0002,332,395,0002,356,245,0002,261,508,0002,249,456,0002,273,628,0002,296,843,0002,237,016,0002,256,035,0002,318,160,0001,989,779,0001,979,816,0001,927,031,0001,897,648,0001,928,325,0001,886,926,0001,866,551,0001,858,205,0001,933,831,0001,895,713,0001,901,237,0001,820,901,0001,853,939,0001,713,181,0001,693,626,0001,799,338,0001,787,802,0001,770,678,0001,780,003,0001,793,578,0001,851,850,0001,715,340,0001,616,276,0001,653,108,0001,565,175,0001,497,122,0001,471,067,0001,445,561,0001,418,079,0001,319,494,0001,336,129,0001,400,629,0001,358,841,0001,326,941,0001,351,736,0001,335,091,0001,302,318,0001,355,246,0001,341,307,0001,364,176,0001,362,910,0001,386,961,00001,348,446,00000
   > Total Current Assets 
0
0
963,640,000
0
1,003,593,000
986,898,000
988,544,000
696,408,000
664,227,000
632,328,000
653,154,000
689,022,000
742,782,000
773,246,000
781,078,000
741,439,000
731,215,000
801,648,000
827,190,000
846,077,000
884,340,000
945,067,000
913,292,000
891,055,000
966,361,000
1,041,886,000
965,958,000
955,231,000
953,576,000
912,122,000
897,537,000
838,927,000
874,694,000
900,763,000
876,665,000
875,921,000
870,173,000
925,200,000
845,619,000
844,734,000
845,514,000
890,258,000
857,159,000
820,130,000
855,596,000
834,150,000
867,514,000
795,979,000
819,902,000
863,294,000
872,588,000
868,715,000
876,454,000
939,331,000
923,354,000
989,281,000
1,059,145,000
1,072,593,000
1,049,954,000
1,317,454,000
1,116,756,000
1,050,102,000
1,050,102,0001,116,756,0001,317,454,0001,049,954,0001,072,593,0001,059,145,000989,281,000923,354,000939,331,000876,454,000868,715,000872,588,000863,294,000819,902,000795,979,000867,514,000834,150,000855,596,000820,130,000857,159,000890,258,000845,514,000844,734,000845,619,000925,200,000870,173,000875,921,000876,665,000900,763,000874,694,000838,927,000897,537,000912,122,000953,576,000955,231,000965,958,0001,041,886,000966,361,000891,055,000913,292,000945,067,000884,340,000846,077,000827,190,000801,648,000731,215,000741,439,000781,078,000773,246,000742,782,000689,022,000653,154,000632,328,000664,227,000696,408,000988,544,000986,898,0001,003,593,0000963,640,00000
       Cash And Cash Equivalents 
0
0
267,460,000
0
276,578,000
279,168,000
312,196,000
199,220,000
184,142,000
140,541,000
142,895,000
166,017,000
206,353,000
216,446,000
210,986,000
189,662,000
191,520,000
242,967,000
264,912,000
234,565,000
258,659,000
303,437,000
391,374,000
373,015,000
421,345,000
438,008,000
396,430,000
371,537,000
388,136,000
340,454,000
360,030,000
311,985,000
366,325,000
348,660,000
340,923,000
314,417,000
307,923,000
331,683,000
331,731,000
309,741,000
306,867,000
331,296,000
311,074,000
259,422,000
311,367,000
277,602,000
318,391,000
239,934,000
286,734,000
306,514,000
326,128,000
301,920,000
318,295,000
350,213,000
315,986,000
313,013,000
361,073,000
381,816,000
376,840,000
561,487,000
333,993,000
253,978,000
253,978,000333,993,000561,487,000376,840,000381,816,000361,073,000313,013,000315,986,000350,213,000318,295,000301,920,000326,128,000306,514,000286,734,000239,934,000318,391,000277,602,000311,367,000259,422,000311,074,000331,296,000306,867,000309,741,000331,731,000331,683,000307,923,000314,417,000340,923,000348,660,000366,325,000311,985,000360,030,000340,454,000388,136,000371,537,000396,430,000438,008,000421,345,000373,015,000391,374,000303,437,000258,659,000234,565,000264,912,000242,967,000191,520,000189,662,000210,986,000216,446,000206,353,000166,017,000142,895,000140,541,000184,142,000199,220,000312,196,000279,168,000276,578,0000267,460,00000
       Short-term Investments 
0
0
246,463,000
0
266,367,000
213,176,000
225,078,000
45,597,000
22,189,000
19,594,000
33,908,000
46,204,000
75,543,000
64,970,000
88,112,000
70,816,000
66,065,000
40,622,000
47,765,000
85,770,000
89,242,000
66,370,000
35,406,000
33,260,000
42,162,000
37,651,000
59,908,000
44,135,000
28,789,000
21,749,000
14,394,000
12,726,000
11,982,000
22,666,000
13,554,000
32,086,000
47,475,000
61,549,000
13,517,000
23,702,000
28,501,000
21,877,000
2,607,000
3,934,000
19,957,000
4,538,000
9,459,000
4,590,000
7,703,000
19,967,000
5,560,000
4,075,000
9,993,000
17,880,000
21,297,000
23,746,000
31,947,000
31,480,000
19,784,000
41,326,000
29,656,000
31,458,000
31,458,00029,656,00041,326,00019,784,00031,480,00031,947,00023,746,00021,297,00017,880,0009,993,0004,075,0005,560,00019,967,0007,703,0004,590,0009,459,0004,538,00019,957,0003,934,0002,607,00021,877,00028,501,00023,702,00013,517,00061,549,00047,475,00032,086,00013,554,00022,666,00011,982,00012,726,00014,394,00021,749,00028,789,00044,135,00059,908,00037,651,00042,162,00033,260,00035,406,00066,370,00089,242,00085,770,00047,765,00040,622,00066,065,00070,816,00088,112,00064,970,00075,543,00046,204,00033,908,00019,594,00022,189,00045,597,000225,078,000213,176,000266,367,0000246,463,00000
       Net Receivables 
0
0
290,546,000
0
228,402,000
262,775,000
291,404,000
239,130,000
250,556,000
274,178,000
330,315,000
260,382,000
261,820,000
295,930,000
336,236,000
267,568,000
263,266,000
291,871,000
300,121,000
283,547,000
287,011,000
319,001,000
332,639,000
324,044,000
333,571,000
394,962,000
332,923,000
360,568,000
351,233,000
376,311,000
327,599,000
336,070,000
316,187,000
347,939,000
309,817,000
337,599,000
314,065,000
347,940,000
319,512,000
333,509,000
323,101,000
347,125,000
342,628,000
358,800,000
335,773,000
366,940,000
347,042,000
360,717,000
332,732,000
345,605,000
357,162,000
381,528,000
375,370,000
390,722,000
404,001,000
456,553,000
463,507,000
462,945,000
445,778,000
477,214,000
504,603,000
505,905,000
505,905,000504,603,000477,214,000445,778,000462,945,000463,507,000456,553,000404,001,000390,722,000375,370,000381,528,000357,162,000345,605,000332,732,000360,717,000347,042,000366,940,000335,773,000358,800,000342,628,000347,125,000323,101,000333,509,000319,512,000347,940,000314,065,000337,599,000309,817,000347,939,000316,187,000336,070,000327,599,000376,311,000351,233,000360,568,000332,923,000394,962,000333,571,000324,044,000332,639,000319,001,000287,011,000283,547,000300,121,000291,871,000263,266,000267,568,000336,236,000295,930,000261,820,000260,382,000330,315,000274,178,000250,556,000239,130,000291,404,000262,775,000228,402,0000290,546,00000
       Other Current Assets 
0
0
53,742,000
0
120,845,000
119,964,000
48,814,000
98,903,000
89,839,000
87,458,000
29,156,000
101,343,000
90,380,000
88,862,000
33,923,000
99,292,000
98,247,000
106,003,000
86,212,000
103,518,000
101,519,000
112,026,000
18,645,000
16,005,000
14,639,000
17,947,000
19,790,000
21,304,000
26,285,000
24,971,000
33,823,000
19,927,000
22,755,000
21,624,000
29,834,000
23,547,000
38,012,000
37,767,000
33,233,000
32,189,000
37,959,000
44,793,000
49,339,000
47,435,000
40,463,000
35,794,000
41,605,000
35,665,000
36,995,000
35,465,000
25,218,000
28,013,000
34,057,000
46,820,000
50,295,000
54,887,000
65,929,000
64,611,000
52,950,000
78,529,000
64,512,000
64,239,000
64,239,00064,512,00078,529,00052,950,00064,611,00065,929,00054,887,00050,295,00046,820,00034,057,00028,013,00025,218,00035,465,00036,995,00035,665,00041,605,00035,794,00040,463,00047,435,00049,339,00044,793,00037,959,00032,189,00033,233,00037,767,00038,012,00023,547,00029,834,00021,624,00022,755,00019,927,00033,823,00024,971,00026,285,00021,304,00019,790,00017,947,00014,639,00016,005,00018,645,000112,026,000101,519,000103,518,00086,212,000106,003,00098,247,00099,292,00033,923,00088,862,00090,380,000101,343,00029,156,00087,458,00089,839,00098,903,00048,814,000119,964,000120,845,000053,742,00000
   > Long-term Assets 
0
0
384,806,000
0
383,368,000
376,012,000
375,632,000
644,899,000
691,019,000
669,990,000
681,937,000
662,714,000
584,159,000
585,595,000
619,551,000
594,690,000
588,277,000
616,429,000
575,929,000
624,990,000
612,781,000
620,106,000
694,285,000
674,424,000
698,122,000
765,267,000
776,421,000
772,800,000
757,011,000
817,005,000
821,548,000
774,719,000
764,291,000
873,831,000
853,887,000
930,458,000
925,701,000
912,358,000
915,350,000
926,613,000
943,680,000
943,775,000
947,533,000
1,016,016,000
1,032,252,000
1,070,687,000
1,397,771,000
1,404,569,000
1,361,883,000
1,382,035,000
1,401,040,000
1,380,741,000
1,385,054,000
1,416,914,000
1,409,041,000
1,492,562,000
1,524,516,000
1,441,355,000
1,406,564,000
1,480,504,000
2,426,265,000
2,318,580,000
2,318,580,0002,426,265,0001,480,504,0001,406,564,0001,441,355,0001,524,516,0001,492,562,0001,409,041,0001,416,914,0001,385,054,0001,380,741,0001,401,040,0001,382,035,0001,361,883,0001,404,569,0001,397,771,0001,070,687,0001,032,252,0001,016,016,000947,533,000943,775,000943,680,000926,613,000915,350,000912,358,000925,701,000930,458,000853,887,000873,831,000764,291,000774,719,000821,548,000817,005,000757,011,000772,800,000776,421,000765,267,000698,122,000674,424,000694,285,000620,106,000612,781,000624,990,000575,929,000616,429,000588,277,000594,690,000619,551,000585,595,000584,159,000662,714,000681,937,000669,990,000691,019,000644,899,000375,632,000376,012,000383,368,0000384,806,00000
       Property Plant Equipment 
0
0
181,447,000
0
184,574,000
184,020,000
184,489,000
191,598,000
186,609,000
185,017,000
190,160,000
191,130,000
189,530,000
190,408,000
199,159,000
195,223,000
199,663,000
207,910,000
218,479,000
218,139,000
218,974,000
223,740,000
191,451,000
188,223,000
192,816,000
205,932,000
202,869,000
205,520,000
203,708,000
202,432,000
200,955,000
192,135,000
182,726,000
188,714,000
191,115,000
193,665,000
182,697,000
184,332,000
181,295,000
179,769,000
183,309,000
174,798,000
173,483,000
251,898,000
254,707,000
260,902,000
268,600,000
267,107,000
265,670,000
255,178,000
264,623,000
269,698,000
266,671,000
267,817,000
269,044,000
280,179,000
280,552,000
269,106,000
286,459,000
290,784,000
296,555,000
289,029,000
289,029,000296,555,000290,784,000286,459,000269,106,000280,552,000280,179,000269,044,000267,817,000266,671,000269,698,000264,623,000255,178,000265,670,000267,107,000268,600,000260,902,000254,707,000251,898,000173,483,000174,798,000183,309,000179,769,000181,295,000184,332,000182,697,000193,665,000191,115,000188,714,000182,726,000192,135,000200,955,000202,432,000203,708,000205,520,000202,869,000205,932,000192,816,000188,223,000191,451,000223,740,000218,974,000218,139,000218,479,000207,910,000199,663,000195,223,000199,159,000190,408,000189,530,000191,130,000190,160,000185,017,000186,609,000191,598,000184,489,000184,020,000184,574,0000181,447,00000
       Goodwill 
0
0
26,377,000
0
20,993,000
21,166,000
22,159,000
267,992,000
105,620,000
103,313,000
101,255,000
101,667,000
93,590,000
92,025,000
94,192,000
88,033,000
83,326,000
89,706,000
95,978,000
99,110,000
95,957,000
101,913,000
116,766,000
114,996,000
124,175,000
136,768,000
136,337,000
138,924,000
136,099,000
136,836,000
150,660,000
139,661,000
137,232,000
187,267,000
175,350,000
203,291,000
199,053,000
192,547,000
212,976,000
219,240,000
226,402,000
226,588,000
225,864,000
220,129,000
219,365,000
226,924,000
267,510,000
276,874,000
273,395,000
267,796,000
284,011,000
284,114,000
284,993,000
293,649,000
303,030,000
334,260,000
353,095,000
324,068,000
328,411,000
355,683,000
403,822,000
387,969,000
387,969,000403,822,000355,683,000328,411,000324,068,000353,095,000334,260,000303,030,000293,649,000284,993,000284,114,000284,011,000267,796,000273,395,000276,874,000267,510,000226,924,000219,365,000220,129,000225,864,000226,588,000226,402,000219,240,000212,976,000192,547,000199,053,000203,291,000175,350,000187,267,000137,232,000139,661,000150,660,000136,836,000136,099,000138,924,000136,337,000136,768,000124,175,000114,996,000116,766,000101,913,00095,957,00099,110,00095,978,00089,706,00083,326,00088,033,00094,192,00092,025,00093,590,000101,667,000101,255,000103,313,000105,620,000267,992,00022,159,00021,166,00020,993,000026,377,00000
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
130,731,000
123,303,000
126,579,000
117,328,000
100,003,000
98,360,000
980,251
129,051,279
1,811,049
138,042,365
1,889,398
109,505,000
118,479,000
120,285,000
125,842,000
127,455,000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000127,455,000125,842,000120,285,000118,479,000109,505,0001,889,398138,042,3651,811,049129,051,279980,25198,360,000100,003,000117,328,000126,579,000123,303,000130,731,000000000000000000000000000000000
       Intangible Assets 
0
0
31,984,000
0
40,495,000
41,808,000
40,601,000
37,787,000
277,307,000
258,415,000
265,922,000
254,199,000
189,040,000
190,115,000
220,085,000
206,365,000
200,082,000
213,011,000
198,864,000
200,149,000
187,468,000
177,624,000
280,120,000
269,019,000
278,238,000
301,156,000
295,844,000
288,245,000
285,656,000
331,764,000
339,202,000
319,620,000
317,754,000
380,522,000
387,419,000
435,142,000
433,413,000
428,018,000
416,912,000
408,998,000
411,140,000
432,884,000
429,707,000
423,704,000
432,338,000
455,406,000
738,507,000
729,400,000
687,306,000
697,164,000
935,438,000
630,322,000
640,981,000
652,251,000
623,431,000
639,834,000
653,629,000
616,538,000
562,496,000
590,424,000
1,532,551,000
1,452,341,000
1,452,341,0001,532,551,000590,424,000562,496,000616,538,000653,629,000639,834,000623,431,000652,251,000640,981,000630,322,000935,438,000697,164,000687,306,000729,400,000738,507,000455,406,000432,338,000423,704,000429,707,000432,884,000411,140,000408,998,000416,912,000428,018,000433,413,000435,142,000387,419,000380,522,000317,754,000319,620,000339,202,000331,764,000285,656,000288,245,000295,844,000301,156,000278,238,000269,019,000280,120,000177,624,000187,468,000200,149,000198,864,000213,011,000200,082,000206,365,000220,085,000190,115,000189,040,000254,199,000265,922,000258,415,000277,307,00037,787,00040,601,00041,808,00040,495,000031,984,00000
       Other Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2,000
2,000
42,442,000
0
1,000
2,000
45,531,000
50,797,000
50,857,000
44,697,000
51,199,000
51,972,000
60,091,000
58,675,000
80,253,000
79,980,000
74,196,000
79,345,000
90,349,000
94,858,000
99,839,000
96,273,000
97,236,000
95,204,000
97,732,000
94,292,000
92,956,000
90,885,000
91,968,000
84,942,000
52,875,000
55,487,000
55,231,000
51,514,000
54,175,000
54,556,000
55,089,000
58,456,000
72,330,000
92,101,000
96,461,000
93,226,000
84,170,000
100,641,000
0
0
00100,641,00084,170,00093,226,00096,461,00092,101,00072,330,00058,456,00055,089,00054,556,00054,175,00051,514,00055,231,00055,487,00052,875,00084,942,00091,968,00090,885,00092,956,00094,292,00097,732,00095,204,00097,236,00096,273,00099,839,00094,858,00090,349,00079,345,00074,196,00079,980,00080,253,00058,675,00060,091,00051,972,00051,199,00044,697,00050,857,00050,797,00045,531,0002,0001,000042,442,0002,0002,0000000000000000000
> Total Liabilities 
0
0
318,225,000
0
307,659,000
302,019,000
310,243,000
329,134,000
336,237,000
298,207,000
313,995,000
346,190,000
346,780,000
365,198,000
382,506,000
352,043,000
253,263,000
295,690,000
383,535,000
317,154,000
307,656,000
340,935,000
384,632,000
386,426,000
420,159,000
477,664,000
475,662,000
446,207,000
447,587,000
465,508,000
540,129,000
503,099,000
485,928,000
540,387,000
549,091,000
581,585,000
544,806,000
566,967,000
589,916,000
590,630,000
604,241,000
636,116,000
639,252,000
677,323,000
683,681,000
672,333,000
1,028,992,000
949,351,000
907,388,000
928,234,000
887,514,000
866,587,000
843,886,000
889,953,000
872,086,000
942,790,000
934,142,000
943,524,000
948,564,000
1,219,542,000
1,903,676,000
1,865,428,000
1,865,428,0001,903,676,0001,219,542,000948,564,000943,524,000934,142,000942,790,000872,086,000889,953,000843,886,000866,587,000887,514,000928,234,000907,388,000949,351,0001,028,992,000672,333,000683,681,000677,323,000639,252,000636,116,000604,241,000590,630,000589,916,000566,967,000544,806,000581,585,000549,091,000540,387,000485,928,000503,099,000540,129,000465,508,000447,587,000446,207,000475,662,000477,664,000420,159,000386,426,000384,632,000340,935,000307,656,000317,154,000383,535,000295,690,000253,263,000352,043,000382,506,000365,198,000346,780,000346,190,000313,995,000298,207,000336,237,000329,134,000310,243,000302,019,000307,659,0000318,225,00000
   > Total Current Liabilities 
0
0
283,553,000
0
277,865,000
271,475,000
277,157,000
283,152,000
261,863,000
228,966,000
239,648,000
273,563,000
275,982,000
307,370,000
314,170,000
288,173,000
253,263,000
295,690,000
313,536,000
317,154,000
307,656,000
340,935,000
340,688,000
341,699,000
375,105,000
424,429,000
420,890,000
391,225,000
395,225,000
409,640,000
413,359,000
396,568,000
383,527,000
400,061,000
399,856,000
401,050,000
365,396,000
395,628,000
421,620,000
438,647,000
447,580,000
494,592,000
495,759,000
464,162,000
483,626,000
466,058,000
798,708,000
647,672,000
616,933,000
635,847,000
592,372,000
581,580,000
554,768,000
597,976,000
687,411,000
740,538,000
761,412,000
705,905,000
726,034,000
991,494,000
1,162,259,000
1,153,715,000
1,153,715,0001,162,259,000991,494,000726,034,000705,905,000761,412,000740,538,000687,411,000597,976,000554,768,000581,580,000592,372,000635,847,000616,933,000647,672,000798,708,000466,058,000483,626,000464,162,000495,759,000494,592,000447,580,000438,647,000421,620,000395,628,000365,396,000401,050,000399,856,000400,061,000383,527,000396,568,000413,359,000409,640,000395,225,000391,225,000420,890,000424,429,000375,105,000341,699,000340,688,000340,935,000307,656,000317,154,000313,536,000295,690,000253,263,000288,173,000314,170,000307,370,000275,982,000273,563,000239,648,000228,966,000261,863,000283,152,000277,157,000271,475,000277,865,0000283,553,00000
       Short-term Debt 
0
0
0
0
0
0
0
54,991,000
30,000,000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2,826,000
1,158,000
869,000
842,000
2,075,000
3,768,000
33,344
4,516,633
84,548
0
0
0
0
0
0
0
0
0
0
0
136,101,000
0
0
0
157,730,000
0
0
0
88,546,000
309,000,000
416,558,000
407,177,000
407,177,000416,558,000309,000,00088,546,000000157,730,000000136,101,0000000000000084,5484,516,63333,3443,768,0002,075,000842,000869,0001,158,0002,826,00000000000000000000000030,000,00054,991,0000000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2,826,000
1,158,000
869,000
842,000
2,075,000
3,768,000
33,344
4,516,633
84,548
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
309,000,000
416,558,000
407,177,000
407,177,000416,558,000309,000,0000000000000000000000084,5484,516,63333,3443,768,0002,075,000842,000869,0001,158,0002,826,000000000000000000000000000000000
       Accounts payable 
0
0
181,561,000
0
87,090,000
100,400,000
177,988,000
93,736,000
93,042,000
98,212,000
139,232,000
97,292,000
94,206,000
114,307,000
190,795,000
103,744,000
87,869,000
115,668,000
178,439,000
106,638,000
108,381,000
114,910,000
187,032,000
185,394,000
212,822,000
220,063,000
226,602,000
199,513,000
202,021,000
199,145,000
181,559,000
158,790,000
154,127,000
162,234,000
182,826,000
152,683,000
125,118,000
137,899,000
140,909,000
138,123,000
145,832,000
191,627,000
185,280,000
140,035,000
160,333,000
139,856,000
171,954,000
132,649,000
113,511,000
111,000,000
124,777,000
108,453,000
111,568,000
136,892,000
130,739,000
152,220,000
146,533,000
134,235,000
140,236,000
138,439,000
147,250,000
150,426,000
150,426,000147,250,000138,439,000140,236,000134,235,000146,533,000152,220,000130,739,000136,892,000111,568,000108,453,000124,777,000111,000,000113,511,000132,649,000171,954,000139,856,000160,333,000140,035,000185,280,000191,627,000145,832,000138,123,000140,909,000137,899,000125,118,000152,683,000182,826,000162,234,000154,127,000158,790,000181,559,000199,145,000202,021,000199,513,000226,602,000220,063,000212,822,000185,394,000187,032,000114,910,000108,381,000106,638,000178,439,000115,668,00087,869,000103,744,000190,795,000114,307,00094,206,00097,292,000139,232,00098,212,00093,042,00093,736,000177,988,000100,400,00087,090,0000181,561,00000
       Other Current Liabilities 
0
0
101,992,000
0
190,775,000
171,075,000
99,169,000
117,655,000
120,605,000
130,754,000
100,416,000
176,271,000
181,776,000
193,063,000
123,375,000
184,429,000
165,394,000
180,022,000
135,097,000
210,516,000
199,275,000
226,025,000
153,656,000
156,305,000
162,283,000
204,366,000
194,288,000
191,712,000
193,204,000
210,495,000
231,800,000
237,778,000
229,400,000
237,827,000
217,030,000
248,367,000
240,278,000
257,729,000
280,711,000
300,524,000
301,748,000
302,965,000
310,479,000
324,127,000
323,293,000
326,202,000
626,754,000
515,023,000
503,422,000
524,847,000
331,494,000
473,127,000
443,200,000
461,084,000
366,554,000
588,318,000
614,879,000
571,670,000
492,115,000
527,784,000
567,127,000
561,290,000
561,290,000567,127,000527,784,000492,115,000571,670,000614,879,000588,318,000366,554,000461,084,000443,200,000473,127,000331,494,000524,847,000503,422,000515,023,000626,754,000326,202,000323,293,000324,127,000310,479,000302,965,000301,748,000300,524,000280,711,000257,729,000240,278,000248,367,000217,030,000237,827,000229,400,000237,778,000231,800,000210,495,000193,204,000191,712,000194,288,000204,366,000162,283,000156,305,000153,656,000226,025,000199,275,000210,516,000135,097,000180,022,000165,394,000184,429,000123,375,000193,063,000181,776,000176,271,000100,416,000130,754,000120,605,000117,655,00099,169,000171,075,000190,775,0000101,992,00000
   > Long-term Liabilities 
0
0
34,672,000
0
29,794,000
30,544,000
33,086,000
45,982,000
74,374,000
69,241,000
74,347,000
72,627,000
70,798,000
57,828,000
68,336,000
63,870,000
62,932,000
71,164,000
70,000,000
64,625,000
66,819,000
63,870,000
64,000
72,000
72,000
90,000
90,000
925,000
1,752,000
1,713,000
1,599,000
1,158,000
869,000
842,000
440,000
3,768,000
3,760,000
3,761,000
3,515,000
3,502,000
3,872,000
1,572,000
1,572,000
1,597,000
2,966,000
3,153,000
3,142,000
2,822,000
2,748,000
1,246,000
295,142,000
285,007,000
289,118,000
291,977,000
184,675,000
202,252,000
172,730,000
237,619,000
222,530,000
228,048,000
741,417,000
711,713,000
711,713,000741,417,000228,048,000222,530,000237,619,000172,730,000202,252,000184,675,000291,977,000289,118,000285,007,000295,142,0001,246,0002,748,0002,822,0003,142,0003,153,0002,966,0001,597,0001,572,0001,572,0003,872,0003,502,0003,515,0003,761,0003,760,0003,768,000440,000842,000869,0001,158,0001,599,0001,713,0001,752,000925,00090,00090,00072,00072,00064,00063,870,00066,819,00064,625,00070,000,00071,164,00062,932,00063,870,00068,336,00057,828,00070,798,00072,627,00074,347,00069,241,00074,374,00045,982,00033,086,00030,544,00029,794,000034,672,00000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
147,659,000
176,767,000
1,557,664
201,246,547
2,849,168
172,813,082
2,350,253
139,952,000
141,152,000
211,564,000
197,089,000
203,122,000
157,915,000
298,857,000
287,707,000
291,141,000
152,578,000
284,699,000
288,674,000
291,314,000
128,986,000
197,383,000
167,708,000
233,241,000
106,852,000
175,679,000
0
0
00175,679,000106,852,000233,241,000167,708,000197,383,000128,986,000291,314,000288,674,000284,699,000152,578,000291,141,000287,707,000298,857,000157,915,000203,122,000197,089,000211,564,000141,152,000139,952,0002,350,253172,813,0822,849,168201,246,5471,557,664176,767,000147,659,0000000000000000000000000000000000000
> Total Stockholder Equity
0
0
1,029,883,000
0
1,079,002,000
1,060,570,000
1,053,581,000
1,012,173,000
1,019,009,000
1,004,111,000
1,021,096,000
1,005,546,000
980,161,000
993,643,000
1,018,123,000
984,086,000
1,025,107,000
1,051,226,000
1,062,026,000
1,089,288,000
1,122,647,000
1,160,371,000
1,268,476,000
1,229,850,000
1,295,181,000
1,374,186,000
1,317,916,000
1,333,796,000
1,323,091,000
1,322,294,000
1,259,209,000
1,190,527,000
1,227,253,000
1,313,552,000
1,271,810,000
1,319,652,000
1,350,907,000
1,366,864,000
1,268,289,000
1,275,921,000
1,282,685,000
1,292,209,000
1,258,396,000
1,249,708,000
1,296,135,000
1,317,446,000
1,289,168,000
1,306,684,000
1,329,628,000
1,368,609,000
1,386,115,000
1,382,869,000
1,417,622,000
1,466,291,000
1,460,308,000
1,539,052,000
1,649,518,000
1,570,424,000
1,507,954,000
1,578,417,000
1,639,345,000
1,503,255,000
1,503,255,0001,639,345,0001,578,417,0001,507,954,0001,570,424,0001,649,518,0001,539,052,0001,460,308,0001,466,291,0001,417,622,0001,382,869,0001,386,115,0001,368,609,0001,329,628,0001,306,684,0001,289,168,0001,317,446,0001,296,135,0001,249,708,0001,258,396,0001,292,209,0001,282,685,0001,275,921,0001,268,289,0001,366,864,0001,350,907,0001,319,652,0001,271,810,0001,313,552,0001,227,253,0001,190,527,0001,259,209,0001,322,294,0001,323,091,0001,333,796,0001,317,916,0001,374,186,0001,295,181,0001,229,850,0001,268,476,0001,160,371,0001,122,647,0001,089,288,0001,062,026,0001,051,226,0001,025,107,000984,086,0001,018,123,000993,643,000980,161,0001,005,546,0001,021,096,0001,004,111,0001,019,009,0001,012,173,0001,053,581,0001,060,570,0001,079,002,00001,029,883,00000
   Common Stock
0
0
103,000,000
0
103,000,000
103,000,000
103,000,000
103,000,000
103,000,000
103,000,000
103,000,000
103,000,000
103,000,000
103,000,000
103,000,000
103,000,000
103,000,000
103,000,000
103,001,000
103,000,000
103,000,000
103,000,000
103,001,000
103,001,000
103,001,000
103,001,000
103,001,000
103,001,000
103,001,000
103,001,000
103,001,000
103,001,000
103,001,000
103,001,000
103,001,000
103,001,000
103,001,000
103,001,000
103,001,000
103,001,000
103,001,000
103,001,000
103,001,000
103,001,000
103,001,000
103,001,000
103,001,000
103,001,000
103,001,000
103,001,000
103,001,000
103,001,000
103,001,000
103,001,000
103,001,000
103,001,000
103,001,000
103,001,000
103,001,000
103,001,000
103,001,000
103,001,000
103,001,000103,001,000103,001,000103,001,000103,001,000103,001,000103,001,000103,001,000103,001,000103,001,000103,001,000103,001,000103,001,000103,001,000103,001,000103,001,000103,001,000103,001,000103,001,000103,001,000103,001,000103,001,000103,001,000103,001,000103,001,000103,001,000103,001,000103,001,000103,001,000103,001,000103,001,000103,001,000103,001,000103,001,000103,001,000103,001,000103,001,000103,001,000103,001,000103,001,000103,000,000103,000,000103,000,000103,001,000103,000,000103,000,000103,000,000103,000,000103,000,000103,000,000103,000,000103,000,000103,000,000103,000,000103,000,000103,000,000103,000,000103,000,0000103,000,00000
   Retained Earnings Total Equity00000000000000000000000000000000000000000000000000000000000000
   Accumulated Other Comprehensive Income 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
265,454,000
171,914,000
166,464,000
200,128,000
247,512,000
355,402,000
386,123,000
313,608,000
340,639,000
444,720,000
504,100,000
412,798,000
412,798,000504,100,000444,720,000340,639,000313,608,000386,123,000355,402,000247,512,000200,128,000166,464,000171,914,000265,454,00000000000000000000000000000000000000000000000000000
   Capital Surplus 00000000000000000000000000000000000000000000000000000000000000
   Treasury Stock00000000000000000000000000000000000000000000000000000000000000
   Other Stockholders Equity 
0
0
-30,463,000
0
91,465,000
68,664,000
55,480,000
35,275,000
37,696,000
15,240,000
43,745,000
33,081,000
-18,479,000
-24,487,000
20,386,000
-19,115,000
-1,025,107,000
28,915,000
41,514,000
123,368,000
130,691,000
164,521,000
300,645,000
282,259,000
312,118,000
380,372,000
309,832,000
364,540,000
294,876,000
266,463,000
183,154,000
193,677,000
183,026,000
239,629,000
154,886,000
326,267,000
317,354,000
308,632,000
189,212,000
308,174,000
265,507,000
226,143,000
163,438,000
292,295,000
268,395,000
264,592,000
280,316,000
284,793,000
284,780,000
302,596,000
64,371,000
161,993,000
162,926,000
163,522,000
165,534,000
155,668,000
156,822,000
157,569,000
156,156,000
146,162,000
147,730,000
148,835,000
148,835,000147,730,000146,162,000156,156,000157,569,000156,822,000155,668,000165,534,000163,522,000162,926,000161,993,00064,371,000302,596,000284,780,000284,793,000280,316,000264,592,000268,395,000292,295,000163,438,000226,143,000265,507,000308,174,000189,212,000308,632,000317,354,000326,267,000154,886,000239,629,000183,026,000193,677,000183,154,000266,463,000294,876,000364,540,000309,832,000380,372,000312,118,000282,259,000300,645,000164,521,000130,691,000123,368,00041,514,00028,915,000-1,025,107,000-19,115,00020,386,000-24,487,000-18,479,00033,081,00043,745,00015,240,00037,696,00035,275,00055,480,00068,664,00091,465,0000-30,463,00000



Balance Sheet

Currency in JPY. All numbers in thousands.




Cash Flow

Currency in JPY. All numbers in thousands.




Income Statement

Currency in JPY. All numbers in thousands.


Latest Income Statement (annual, 2023-03-31)

Gross Profit (+$)
totalRevenue1,518,619,000
Cost of Revenue-326,789,000
Gross Profit1,191,830,0001,191,830,000
 
Operating Income (+$)
Gross Profit1,191,830,000
Operating Expense-906,400,000
Operating Income285,430,000285,430,000
 
Operating Expense (+$)
Research Development276,128,000
Selling General Administrative630,272,000
Selling And Marketing Expenses-
Operating Expense906,400,000906,400,000
 
Net Interest Income (+$)
Interest Income8,110,000
Interest Expense-3,620,000
Other Finance Cost-5,159,000
Net Interest Income-669,000
 
Pretax Income (+$)
Operating Income285,430,000
Net Interest Income-669,000
Other Non-Operating Income Expenses-
Income Before Tax (EBT)131,101,000439,759,000
EBIT - interestExpense = 281,810,000
132,361,000
102,334,000
Interest Expense3,620,000
Earnings Before Interest and Taxes (EBIT)285,430,000134,721,000
Earnings Before Interest and Taxes (EBITDA)391,168,000
 
After tax Income (+$)
Income Before Tax131,101,000
Tax Provision-33,647,000
Net Income From Continuing Ops98,714,00097,454,000
Net Income98,714,000
Net Income Applicable To Common Shares-
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses1,233,189,000
Total Other Income/Expenses Net-154,329,000669,000
 

Technical Analysis of Astellas
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Astellas. The general trend of Astellas is BEARISH with 100.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Astellas's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-100.0%) Bearish trend (100.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Astellas Pharma Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 10.29 < 10.53 < 11.15.

The bearish price targets are: .

Tweet this
Astellas Pharma Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Astellas Pharma Inc. The current mas is .

The long score for the Moving Averages is 0/14.
The longshort score for the Moving Averages is -14/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Astellas Pharma Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Astellas Pharma Inc. The current macd is -0.39151363.

The long score for the Moving Average Convergence/Divergence (MACD) is 0/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -4/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Astellas price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Astellas. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Astellas price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Astellas Pharma Inc Daily Moving Average Convergence/Divergence (MACD) ChartAstellas Pharma Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Astellas Pharma Inc. The current adx is 23.07.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -2/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Astellas shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX < 25 && ADX trending up: The ADX is below 25 and indicates a weak or no trend. However, the ADX is rising and a new bearish trend could be forming. -1
Astellas Pharma Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Astellas Pharma Inc. The current sar is 10.66.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Astellas Pharma Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Astellas Pharma Inc. The current rsi is 25.15. The current phase is Oversold in bear market.

The long score for the Relative Strength Index (RSI) is 2/13.
The longshort score for the Relative Strength Index (RSI) is 2/(-13 +13).

  • Oversold in bear market: Short-term excessive selling, potential for relief rally. Be cautious, consider taking short-term long positions. +1
  • Trending up: The RSI is trending up. +1
Astellas Pharma Inc Daily Relative Strength Index (RSI) ChartAstellas Pharma Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Astellas Pharma Inc. The current phase is Oversold in bear market.

The long score for the Stochastic Oscillator is 3/6.
The longshort score for the Stochastic Oscillator is 0/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Astellas price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Astellas Pharma Inc Daily Stochastic Oscillator ChartAstellas Pharma Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Astellas Pharma Inc. The current cci is -121.25020734.

The long score for the Commodity Channel Index (CCI) is 0/1.
The longshort score for the Commodity Channel Index (CCI) is -1/(-1 +1).

  • CCI < -100: The CCI is below -100, it indicates that the price is significantly below its average, suggesting a potential oversold condition. -1
Astellas Pharma Inc Daily Commodity Channel Index (CCI) ChartAstellas Pharma Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Astellas Pharma Inc. The current cmo is -54.30116114.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Astellas Pharma Inc Daily Chande Momentum Oscillator (CMO) ChartAstellas Pharma Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Astellas Pharma Inc. The current willr is -84.3902439.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
Astellas Pharma Inc Daily Williams %R ChartAstellas Pharma Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Astellas Pharma Inc.

Astellas Pharma Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Astellas Pharma Inc. The current atr is 0.31952014.

Astellas Pharma Inc Daily Average True Range (ATR) ChartAstellas Pharma Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Astellas Pharma Inc. The current obv is -1,859,458.

Astellas Pharma Inc Daily On-Balance Volume (OBV) ChartAstellas Pharma Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Astellas Pharma Inc. The current mfi is 42.39.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Astellas Pharma Inc Daily Money Flow Index (MFI) ChartAstellas Pharma Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Astellas Pharma Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-28STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-11-30STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-01WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-04STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-05MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-12-06STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-07DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-12-08DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-11SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2023-12-12CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2023-12-13MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-14STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-15WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2023-12-19STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-20STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-21STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-26MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2023-12-28DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-02STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-03CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-04STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-08STOCH LONG EXITThe %K line crosses below the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-01-10STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-01-11STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-16STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-17SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-18MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-01-19DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-25STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-01SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-02SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-02-05CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-08STOCH SHORT EXITThe %K line crosses above the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-02-13RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2024-02-16MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-02-20DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-02-21DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-23STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-27STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-01STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-04CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-03-05STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-06CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-03-08MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-03-11MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-13MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-03-15MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-19CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-21CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-22DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-25CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-26DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-27DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-28DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-01DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-04-02DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-03MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-04DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-08SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-10STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-04-11RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2024-04-12STOCH SHORT EXITThe %K line crosses above the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-15STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-16STOCH SHORT EXITThe %K line crosses above the %D line.

6.3. Candlestick Patterns

Astellas Pharma Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Astellas Pharma Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5025.146
Ma 20Greater thanMa 5010.389
Ma 50Greater thanMa 10010.701
Ma 100Greater thanMa 20011.246
OpenGreater thanClose9.460
Total0/5 (0.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Astellas with someone you think should read this too:
  • Are you bullish or bearish on Astellas? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Astellas? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Astellas Pharma Inc

I send you an email if I find something interesting about Astellas Pharma Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Astellas Pharma Inc.

Receive notifications about Astellas Pharma Inc in your mailbox!